Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance.
about
Neonatal Citrulline Supplementation and Later Exposure to a High Fructose Diet in Rats Born with a Low Birth Weight: A Preliminary ReportUltra high performance liquid chromatography-high resolution mass spectrometry plasma lipidomics can distinguish between canine breeds despite uncontrolled environmental variability and non-standardized diets.Sphingolipids and Lipoproteins in Health and Metabolic Disorders.Loss of miR-141/200c ameliorates hepatic steatosis and inflammation by reprogramming multiple signaling pathways in NASH.Dual Expression of the Salmonella Effector SrfJ in Mammalian Cells and Plants.A synergistic effect of Cremophor and beta glucosylceramide to exert liver and sugar protection.Glycosphingolipids Prevent APAP and HMG-CoA Reductase Inhibitors-mediated Liver Damage: A Novel Method for “Safer Drug” Formulation that Prevents Drug-induced Liver Injury.Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment.Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASHIncreased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease
P2860
Q33616820-00272852-82DB-4040-8734-975DD409EBB0Q37562546-7EB589EB-5DEA-47D8-A0D2-0326A9DF154DQ39277798-EBF93045-5591-4812-80DD-1DCAD440D644Q46270590-84263106-4847-4CD8-8E60-5AA0E1E159B0Q47115985-573C0111-F95B-4ED8-9CB0-2A70AA7F93CBQ55014958-E96D2386-BC9F-4A54-BE35-7DFC2A522C20Q55313239-2E6E35E3-F539-499C-AAB4-C8FFCB81F356Q55323878-BBD55D9C-A3AB-45AD-A0B7-A154BE853348Q57210121-852B189E-B5CA-4D96-B85D-C85C1397A7D1Q58747079-E57500E0-D10D-4498-A3BA-9CCA88144E4F
P2860
Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Compounds of the sphingomyelin ...... isease and insulin resistance.
@en
type
label
Compounds of the sphingomyelin ...... isease and insulin resistance.
@en
prefLabel
Compounds of the sphingomyelin ...... isease and insulin resistance.
@en
P2860
P356
P1476
Compounds of the sphingomyelin ...... isease and insulin resistance.
@en
P2093
Yaron Ilan
P2860
P304
P356
10.1152/AJPGI.00095.2016
P577
2016-05-12T00:00:00Z